WO2006126082A3 - Pyridine [3,4-b] pyrazinones - Google Patents

Pyridine [3,4-b] pyrazinones Download PDF

Info

Publication number
WO2006126082A3
WO2006126082A3 PCT/IB2006/001387 IB2006001387W WO2006126082A3 WO 2006126082 A3 WO2006126082 A3 WO 2006126082A3 IB 2006001387 W IB2006001387 W IB 2006001387W WO 2006126082 A3 WO2006126082 A3 WO 2006126082A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazinones
pde
pyridine
inhibitors
compounds
Prior art date
Application number
PCT/IB2006/001387
Other languages
English (en)
Other versions
WO2006126082A2 (fr
Inventor
Alan George Benson
Andrew Simon Bell
David Graham Brown
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Robert Owen Hughes
Eric Jon Jacobsen
Brent Virgil Mischke
John Major Molyneaux
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
Jr Donald Joseph Rogier
John Keith Walker
Original Assignee
Pharmacia & Upjohn Co Llc
Alan George Benson
Andrew Simon Bell
David Graham Brown
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Robert Owen Hughes
Eric Jon Jacobsen
Brent Virgil Mischke
John Major Molyneaux
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
Jr Donald Joseph Rogier
John Keith Walker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Alan George Benson, Andrew Simon Bell, David Graham Brown, David Louis Brown, Yvette Marlene Fobian, John Nicholas Freskos, Steven Edward Heasley, Robert Owen Hughes, Eric Jon Jacobsen, Brent Virgil Mischke, John Major Molyneaux, Dafydd Rhys Owen, Michael John Palmer, Christopher Phillips, Jr Donald Joseph Rogier, John Keith Walker filed Critical Pharmacia & Upjohn Co Llc
Priority to CA002608672A priority Critical patent/CA2608672A1/fr
Publication of WO2006126082A2 publication Critical patent/WO2006126082A2/fr
Publication of WO2006126082A3 publication Critical patent/WO2006126082A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne des composés, des tautomères de ces composés, et des sels pharmaceutiquement acceptables de ces composés ou tautomères. Ces composés possèdent une structure représentée par la formule (I), dans laquelle R2, X6, Y6, R6 et R8 sont définis dans les pièces descriptives de la demande. Des compositions pharmaceutiques correspondantes, des procédés de traitement, des procédés de synthèse et des intermédiaires sont également divulgués.
PCT/IB2006/001387 2005-05-24 2006-05-17 Pyridine [3,4-b] pyrazinones WO2006126082A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002608672A CA2608672A1 (fr) 2005-05-24 2006-05-17 Pyridine [3,4-b] pyrazinones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413905P 2005-05-24 2005-05-24
US60/684,139 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006126082A2 WO2006126082A2 (fr) 2006-11-30
WO2006126082A3 true WO2006126082A3 (fr) 2007-01-25

Family

ID=37056557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001387 WO2006126082A2 (fr) 2005-05-24 2006-05-17 Pyridine [3,4-b] pyrazinones

Country Status (2)

Country Link
CA (1) CA2608672A1 (fr)
WO (1) WO2006126082A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513831T1 (de) * 2006-04-21 2011-07-15 Pfizer Prod Inc Pyridinä3,4-büpyrazinone
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
ES2632964T3 (es) 2008-03-05 2017-09-18 Merck Patent Gmbh Derivados de piridopirazinonas estimuladores de la secreción de insulina, métodos para obtenerlos y uso de los mismos para el tratamiento de la diabetes
WO2012131539A1 (fr) 2011-03-31 2012-10-04 Pfizer Inc. Nouvelles pyridones bicycliques
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
EP2751116B1 (fr) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
EP2935282A1 (fr) 2012-12-19 2015-10-28 Pfizer Inc. Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
KR101886945B1 (ko) 2014-04-01 2018-08-08 화이자 인코포레이티드 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온
MD20160105A2 (ro) 2014-04-10 2017-03-31 Pfizer Inc. 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CU20170007A7 (es) 2014-08-06 2017-06-05 Pfizer Compuestos de imidazopiridazina
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
EP3419979B1 (fr) 2016-02-23 2020-01-29 Pfizer Inc Composés 6,7-dihydro-5 h-pyrazolo [5,1-b][1,3]oxazine-2-carboxamide
EP3872078A1 (fr) 2016-07-01 2021-09-01 Pfizer Inc. Dérivés de 5,7-dihydro-pyrrolo-pyridine destinés à être utilisés dans le traitement de la dépression, l'angoisse et les troubles paniques
JP7263266B2 (ja) 2017-06-22 2023-04-24 ファイザー・インク ジヒドロ－ピロロ－ピリジン誘導体
WO2019183636A1 (fr) 2018-03-23 2019-09-26 Pfizer Inc. Dérivés azaspiro de pipérazine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076954A1 (fr) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (fr) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
WO2004031189A1 (fr) * 2002-09-30 2004-04-15 Bristol-Myers Squibb Pharma Company Pyrazinones pyridino et pyrimidino destinees au traitement de l'anxiete et de la depression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (fr) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
WO2002076954A1 (fr) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
WO2004031189A1 (fr) * 2002-09-30 2004-04-15 Bristol-Myers Squibb Pharma Company Pyrazinones pyridino et pyrimidino destinees au traitement de l'anxiete et de la depression

Also Published As

Publication number Publication date
CA2608672A1 (fr) 2006-11-30
WO2006126082A2 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006126082A3 (fr) Pyridine [3,4-b] pyrazinones
WO2006126081A3 (fr) Pyridine [2,3-b] pyrazinones
MY148583A (en) Pyridine [3,4-b] pyrazinones
WO2006032342A3 (fr) Medicament contenant des composes carbonyles et leur utilisation
WO2006011050A3 (fr) Derives de pyridine
WO2006087543A8 (fr) Composés antibactériens dérivés de pipéridine
WO2007135527A3 (fr) Composés de benzimidazolyle
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
WO2005103037A3 (fr) Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments
WO2005075450A3 (fr) Nouveaux composes spiro-pentacycliques
WO2009016560A3 (fr) Dérivés de trans-3-aza-bicyclo[3.1.0]hexane
WO2008121687A3 (fr) Composés imidazo[1,2-a]pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur
TW200716628A (en) Novel compounds
WO2006124490A3 (fr) Heterocycles utilises comme agonistes du recepteur de l'acide nicotinique dans le traitement de la dyslipidemie
WO2004101528A3 (fr) Inhibiteurs de la gfat
WO2005080352A3 (fr) Derives de quinazoline et leur utilisation therapeutique
WO2006065590A3 (fr) Compositions antivirales a base de pyridines et de pyrimidines
WO2007046867A3 (fr) Derives de piperidine et leurs utilisations comme agents therapeutiques
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
EP1784402A4 (fr) Derives pyrrolo[3,2-c]pyridine et procedes de preparation de ces derniers
WO2005021544A3 (fr) Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
WO2009156951A3 (fr) Composés de 5,6,7,8-tétrahydro-imidazo[1,5-a]pyrazine
WO2008104473A3 (fr) Inhibiteurs de kinase et procédés d'utilisation de ces derniers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2608672

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744778

Country of ref document: EP

Kind code of ref document: A2